Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.

Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.

Global Market Report23:21 ET

AstraZeneca Announces Share Capital and Voting Rights

TipRanksDec 2 10:04 ET

Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?

Yahoo FinanceDec 2 07:46 ET

The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis

Yahoo FinanceDec 2 05:00 ET

USA Stock Market Outlook | Three major equity index futures rise together, US retailers prepare for Black Friday, the market will close 3 hours early on Friday.

On November 29 (Friday) during pre-market trading, all three major equity index futures in the U.S. rose.

Zhitong FinanceNov 29 06:31 ET

Astrazeneca (AZN.US) Class 1 new drug approved for clinical trials in China for the first time, aiming to develop treatment for heart failure.

Astrazeneca (AZN.US) has received an implied license for clinical trials of its Class 1 new drug AZD5462 in china, which is intended for the treatment of heart failure.

Zhitong FinanceNov 29 01:38 ET